BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...CRISPR systems. The CRISPR-Phage technology being developed by Locus Biosciences Inc....
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...and lopinavir/ritonavir (see “Coronavirus Biology” ). Locus shares data on CRISPR-expressing phages for C. diff Locus Biosciences Inc....
...Cas3 KEAP1 - Kelch-like ECH-associated protein 1 NFE2L2 (NRF2) - Nuclear factor (erythroid-derived 2)-like 2 BioCentury Staff Locus Biosciences Inc. Harvard...
BioCentury | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

...system had editing efficiencies up to 50% in human cell lines. Another gene editing company, Locus Biosciences Inc....
BioCentury | Oct 7, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

...counterpart. In a paper published in Nature Biotechnology on Sept. 23, a team led by Locus Biosciences Inc....
...Francisella 1; HBE1 - Hemoglobin subunit ε1; IL-1RA (IL1RN) - Interleukin-1 receptor antagonist Lauren Martz, Associate Editor Locus Biosciences Inc. Duke...
BioCentury | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

...counterpart. In a paper published in Nature Biotechnology on Sept. 23, a team led by Locus Biosciences Inc....
...Francisella 1; HBE1 - Hemoglobin subunit ε1; IL-1RA (IL1RN) - Interleukin-1 receptor antagonist Lauren Martz, Associate Editor Locus Biosciences Inc. Duke...
BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

...therapy in other disease areas with well established microbiome links, including metabolic and CNS diseases. Locus Biosciences Inc....
...for infectious disease and immune modulation Companies and Institutions Mentioned Eligo Bioscience S.A.S., Paris, France Locus Biosciences Inc....
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

...are targeting endogenous CRISPR machinery in bacterial pathogens, all of which raised money in 2017: Locus Biosciences Inc....
BioCentury | Mar 11, 2019
Financial News

$50M series A for CRISPR microbiome play SNIPR Biome

...parallel, Grøndahl said, with the first program expected to enter the clinic in two years. Locus Biosciences Inc....
BioCentury | Jan 4, 2019
Company News

Janssen, Locus partner on CRISPR-Cas3 bacteriophages

...Janssen Pharmaceuticals Inc. partnered with Locus Biosciences Inc. (Morrisville, N.C.) to develop and commercialize CRISPR-Cas3-enhanced bacteriophage therapies against...
...Locus Biosciences Inc., Morrisville, N.C. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Elizabeth S. Eaton Janssen Johnson & Johnson Locus Biosciences Inc. CRISPR-associated...
BioCentury | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

...using alternative CRISPR systems that employ CasX, CasY and ARMAN endonucleases to treat viral infections. Locus Biosciences Inc....
...BioTherapeutics Inc., Philadelphia, Pa. Intellia Therapeutics Inc. (NASDAQ:NTLA), Cambridge, Mass. Locana Inc., San Diego, Calif. Locus Biosciences Inc....
Items per page:
1 - 10 of 17
BioCentury | Oct 10, 2020
Product Development

Next-generation CRISPR technologies keep on building

...CRISPR systems. The CRISPR-Phage technology being developed by Locus Biosciences Inc....
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

...and lopinavir/ritonavir (see “Coronavirus Biology” ). Locus shares data on CRISPR-expressing phages for C. diff Locus Biosciences Inc....
...Cas3 KEAP1 - Kelch-like ECH-associated protein 1 NFE2L2 (NRF2) - Nuclear factor (erythroid-derived 2)-like 2 BioCentury Staff Locus Biosciences Inc. Harvard...
BioCentury | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

...system had editing efficiencies up to 50% in human cell lines. Another gene editing company, Locus Biosciences Inc....
BioCentury | Oct 7, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

...counterpart. In a paper published in Nature Biotechnology on Sept. 23, a team led by Locus Biosciences Inc....
...Francisella 1; HBE1 - Hemoglobin subunit ε1; IL-1RA (IL1RN) - Interleukin-1 receptor antagonist Lauren Martz, Associate Editor Locus Biosciences Inc. Duke...
BioCentury | Sep 25, 2019
Tools & Techniques

Locus co-founders open door to new CRISPR systems

...counterpart. In a paper published in Nature Biotechnology on Sept. 23, a team led by Locus Biosciences Inc....
...Francisella 1; HBE1 - Hemoglobin subunit ε1; IL-1RA (IL1RN) - Interleukin-1 receptor antagonist Lauren Martz, Associate Editor Locus Biosciences Inc. Duke...
BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

...therapy in other disease areas with well established microbiome links, including metabolic and CNS diseases. Locus Biosciences Inc....
...for infectious disease and immune modulation Companies and Institutions Mentioned Eligo Bioscience S.A.S., Paris, France Locus Biosciences Inc....
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

...are targeting endogenous CRISPR machinery in bacterial pathogens, all of which raised money in 2017: Locus Biosciences Inc....
BioCentury | Mar 11, 2019
Financial News

$50M series A for CRISPR microbiome play SNIPR Biome

...parallel, Grøndahl said, with the first program expected to enter the clinic in two years. Locus Biosciences Inc....
BioCentury | Jan 4, 2019
Company News

Janssen, Locus partner on CRISPR-Cas3 bacteriophages

...Janssen Pharmaceuticals Inc. partnered with Locus Biosciences Inc. (Morrisville, N.C.) to develop and commercialize CRISPR-Cas3-enhanced bacteriophage therapies against...
...Locus Biosciences Inc., Morrisville, N.C. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Elizabeth S. Eaton Janssen Johnson & Johnson Locus Biosciences Inc. CRISPR-associated...
BioCentury | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

...using alternative CRISPR systems that employ CasX, CasY and ARMAN endonucleases to treat viral infections. Locus Biosciences Inc....
...BioTherapeutics Inc., Philadelphia, Pa. Intellia Therapeutics Inc. (NASDAQ:NTLA), Cambridge, Mass. Locana Inc., San Diego, Calif. Locus Biosciences Inc....
Items per page:
1 - 10 of 17